Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Regenxbio Inc.
US FDA’s Peter Marks says companies are not exchanging information about adenoviral factors, which is probably slowing down the field. He describes NIH's plans for a bespoke gene therapy consortium for vector generation and continued efforts for regulatory harmonization.
The Swiss firm that discovered Biogen’s Alzheimer’s therapy aducanumab has built a pipeline of clinical programs across neurological and other diseases and may seek additional partners as candidates advance.
The Swiss biotech believes the clinical success of OCS-01, a novel eye drop formulation of dexamethasone for diabetic macular edema, validates not only the drug but also Oculis's proprietary technology, allowing it to build up a pipeline of products for both retinal and front of the eye diseases.
Novel therapeutic strategies for Parkinson’s disease have brought a renewed sense of optimism to those researching this neurodegenerative disorder. Numerous treatment avenues are being explored, including small molecules, gene therapy, cell therapy and medical devices to stimulate nerves deep in the brain. Digital also gets a look-in, being useful for analyzing gait and other symptoms, and addressing both mental and physical issues.
- Drug Delivery
- Drug Discovery Tools
- Gene Therapy, Cell Therapy
- Large Molecule
Drug Discovery Tools
- Other Names / Subsidiaries
- ReGenX, LLC
- ReGenX Biosciences, LLC